The reputation of the biopharmaceutical industry continues to be battered by claims of illegal detailing of drugs or questionable sales and marketing practices. And now a new twist from the hands of Martin Shkreli, the CEO of Turing Pharmaceuticals and a former hedge fund manager. He raised the price of a 60 year old generic drug Daraprim acquired by his company in August from $13.50 to $750 a tablet, overnight.
According to the report in Forbes, Shkreli’s actions are being viewed as typical drug company behavior and yet another example of the industry’s price gouging. Daraprim was originally discovered, developed and manufactured by GlaxoSmithKline (GSK). The Daraprim patent expired decades ago and the drug is now generic, thus allowing others to make it.
However, it is a small product and no real competition has arisen. In 2010, GSK sold the marketing rights for Daraprim to CorePharma. Sales of Daraprim were less than $1 million in 2010 based on a price of about $1/pill. CorePharma raised the price to $13.50, which itself is surprising. But given the importance of the drug and the modest number of prescriptions per year (about 12,700), there was little complaint. However, a series of deals brought Daraprim to Turing Pharmaceuticals and the price was immediately increased to $750 a pill.
Turing’s price increase is not an isolated example. Although some price increases have been caused by shortages, others have resulted from a business strategy of buying old neglected drugs and turning them into high-priced “specialty drugs.”
Cycloserine, a drug used to treat dangerous multidrug-resistant tuberculosis, was just increased in price to $10,800 for 30 pills from $500 after its acquisition by Rodelis Therapeutics. Scott Spencer, general manager of Rodelis, said the company needed to invest to make sure the supply of the drug remained reliable. He said the company provided the drug free to certain needy patients.
Valeant Pharmaceuticals acquired two heart drugs, Isuprel and Nitropress, from Marathon Pharmaceuticals and promptly raised their prices by 525 percent and 212 percent respectively. Marathon had acquired the drugs from another company in 2013 and had quintupled their prices. Another drug, Doxycycline, an antibiotic, went from $20 a bottle in October 2013 to $1,849 by April 2014.
This is not the first time the 32-year-old Shkreli has been the center of controversy. In 2011, Mr. Shkreli started another company, Retrophin, which also acquired old neglected drugs and sharply raised their prices. Retrophin’s board fired Mr. Shkreli a year ago. Last month, it filed a complaint in Federal District Court in Manhattan, accusing him of using Retrophin as a personal piggy bank to pay back angry investors in his hedge fund. Shkreli has denied the accusations. He has filed for arbitration against his old company, which he says owes him at least $25 million in severance.